Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 145Unknown 24Terminated 19Active not recruiting 12Withdrawn 10Recruiting 4Suspended 2Not yet recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Sarcoma, Ewing 2Rhabdomyosarcoma 2Recurrence 2Wilms Tumor 1Solid Tumor Cancer 1Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Neoplasm, Residual 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Lymphoma 1Leukemia 1Enteropathy-Associated T-Cell Lymphoma 1Ann Arbor Stage II Mantle Cell Lymphoma 1

Interventions

Rituximab 3Cyclophosphamide 3obinutuzumab 2fludarabine 2daratumumab 2Specimen Handling 2Prednisone 2Magnetic Resonance Spectroscopy 2Immunotherapy, Adoptive 2Dexamethasone 2Bortezomib 2Biopsy 2Bendamustine Hydrochloride 2zanubrutinib 1venetoclax 1tafasitamab 1selinexor 1prednylidene 1polatuzumab vedotin 1pegaspargase 1orelabrutinib 1nelarabine 1merphos 1glofitamab 1exifone 1dexamethasone acetate 1dexamethasone 21-phosphate 1deltacortene 1calaspargase pegol 1auricularum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Lymphoma × Vincristine × Clear all
NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Children's Oncology Group

Phase 2/3 Not yet recruiting
1,708 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡